In laboratory settings, it has been examined for its interaction with GLP-1 pathways and its role in neuroendocrine and metabolic signaling
American Heart Scientific Sessions: Philadelphia November 1113, 2023
Retatrutide is a new treatment for those who are overweight or living with obesity The medication has not yet received approval or become available It works by targeting three different receptors at the same time Clinical trials to date suggest potential weight loss of up to 24% Side effects seem to be similar to those seen with other GLP-1 medications About Retatrutide Retatrutide is a new treatment for those who are overweight or living with obesity The medication has not yet received approval or become available It works by targeting three different receptors at the same time Clinical trials to date suggest potential weight loss of up to 24% Side effects seem to be similar to those seen with other GLP-1 medications Retatrutide: new weight loss medication in development Retatrutide is a new medication that is currently attracting considerable attention as a potential treatment for overweight and obesity
Individuals on Tirzepatide (n = 50) reported a median dose of 7.5 mg [range 0.515 mg], and on Semaglutide variants: Ozempic or Wegovy (n = 54) reported a median dose of 1 [range 0.252.4] and Rybelsus (n = 2) reported doses of 7 mg and 14 mg
The exact ingredients can vary between brands, but GLP-1 patches typically contain a combination of natural extracts and vitamins , like: berberine (the main active ingredient, thought to support GLP-1 release) green tea extract cinnamon extract mint pomegranate extract a selection of vitamins None of these are clinically approved for weight loss , and the amounts absorbed through the skin are not well studied or proven to be effective
